Cdc25A Antibody (DCS-120): sc-56264
- Cdc25A Antibody (DCS-120) is a mouse monoclonal IgG2a κ, cited in 9 publications, provided at 200 µg/ml
- raised against purified recombinant Cdc25A
- recommended for detection of Cdc25A of mouse, rat and human origin by WB, IP, IF and IHC(P)
- See Cdc25A (F-6): sc-7389 for Cdc25A antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Cdc25A Antibody (DCS-120). This work is in progress.
Cdc25A Antibody (DCS-120) is a mouse monoclonal IgG2a antibody that detects Cdc25A in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Cdc25A plays a crucial role in cell cycle regulation, particularly in the transition from G2 phase to mitosis, by acting as a phosphatase that dephosphorylates and activates the cyclin-dependent kinase Cdc2. This activation is essential for the proper progression of mitosis, as it allows the cell to enter the mitotic phase and ensures accurate chromosome segregation. Dysregulation of Cdc25A can lead to uncontrolled cell division and has been implicated in various cancers, making Cdc25A a significant target for therapeutic intervention. Cdc25A is primarily located in the nucleus, where Cdc25A interacts with other cell cycle regulators, and Cdc25A activity is tightly controlled by phosphorylation and dephosphorylation events. The Cdc25 family of proteins, which includes Cdc25A, Cdc25B, and Cdc25C, share conserved sequences that are critical for their phosphatase activity, highlighting the importance of these proteins in maintaining cellular homeostasis and responding to DNA damage. anti-Cdc25A antibody (DCS-120) is an invaluable tool for researchers studying cell cycle dynamics and the molecular mechanisms underlying cell proliferation and cancer.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Cdc25A Antibody (DCS-120) References:
- Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies. | Wang, Z., et al. 2008. Anticancer Agents Med Chem. 8: 863-71. PMID: 19075569
- CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability. | Dozier, C., et al. 2017. Oncogene. 36: 3781-3788. PMID: 28192398
- Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity. | Qi, D., et al. 2018. J Virol. 92: PMID: 30021902
- HAUSP stabilizes Cdc25A and protects cervical cancer cells from DNA damage response. | Das, S., et al. 2020. Biochim Biophys Acta Mol Cell Res. 1867: 118835. PMID: 32860838
- Activation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition. | Ditano, JP., et al. 2021. Cell Cycle. 20: 1308-1319. PMID: 34156324
- Hsa_circ_0014879 regulates the radiosensitivity of esophageal squamous cell carcinoma through miR-519-3p/CDC25A axis. | Liu, Z., et al. 2022. Anticancer Drugs. 33: e349-e361. PMID: 34407051
- Role of miR-100-5p and CDC25A in breast carcinoma cells. | Li, X., et al. 2022. PeerJ. 9: e12263. PMID: 35036112
- Small-Molecule Cdc25A Inhibitors Protect Neuronal Cells from Death Evoked by NGF Deprivation and 6-Hydroxydopamine. | Pramanik, SK., et al. 2023. ACS Chem Neurosci. 14: 1226-1237. PMID: 36942687
- A novel selenium analog of HDACi-based twin drug induces apoptosis and cell cycle arrest via CDC25A to improve prostate cancer therapy. | Shi, Z., et al. 2024. Theranostics. 14: 3565-3582. PMID: 38948069
- m6A modification enhances the stability of CDC25A promotes tumorigenicity of esophagogastric junction adenocarcinoma via cell cycle. | Pan, Y., et al. 2024. Int J Biol Sci. 20: 4209-4221. PMID: 39247830
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdc25A Antibody (DCS-120) | sc-56264 | 200 µg/ml | $322.00 |